Will Besotivan be included in medical insurance in 2025? Come check it out!

Belzutifan As a new typeHIF-2α inhibitor, it has been approved for marketing in China and is mainly used to treat von Hippel-Lindau disease (VHL)-related renal cell carcinoma (RCC), central nervous system hemangioblastoma and certain pancreatic cancers that do not require immediate surgery. Although the clinical application of this drug has begun in China, the specific situation of whether it will be included in the medical insurance list is still unclear. Due to the short time the drug has been on the market, the medical insurance policy and reimbursement scope have not yet been fully announced.

Currently, bezotivan is an imported drug and is relatively expensive. Considering that the patient base of VHL, a rare disease, is small and the cost of drug research and development is high, the price of besetifan is higher than that of traditional drugs, and it is not currently listed in China's national medical insurance directory. Therefore, if patients want to purchase the drug, they still need to pay for it at their own expense or purchase it cross-border.

Nevertheless, as an innovative therapeutic drug, bezotivan has gradually attracted attention for its potential efficacy and market demand. With the deepening of the clinical application of bezotivan in China, it is possible that the drug will be included in the medical insurance catalog through medical insurance negotiations or other policy channels in the future to reduce the financial burden on patients. Especially when the therapeutic effect on patients with von Hippel-Lindau disease and renal cell carcinoma is remarkable, the drug is more likely to be included in medical insurance.

Regarding the medical insurance policy of bezotevan, patients can learn whether the drug will be included in the medical insurance catalog by paying attention to the latest developments from the National Medical Insurance Bureau and local medical insurance departments. Changes in the medical insurance catalog are usually related to drug efficacy evaluation, market demand and drug pricing. Therefore, whether bestivan can be included in medical insurance requires further policy discussion and evaluation.

Reference materials:https://www.welireg.com/